NCT00523653

Brief Summary

Dilated cardiomyopathy (DCM) affects about 200,000 Canadians. Eighty percent of these cases are of unclear cause, often occuring in families. We believe that mutations in specific already-identified genes contribute to DCM in Quebec and that certain mutations may account for a significant proportion of cases due to the well-documented "founder effect". Two hundred patients with DCM followed in our Heart Function Clinic will be approached for one blood sample at their routine clinic visit to test this hypothesis. The samples will be tested in the Laboratory of Cardiovascular Genetics at the Royal Victoria Hospital.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2008

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 29, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 31, 2007

Completed
4 months until next milestone

Study Start

First participant enrolled

January 1, 2008

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2008

Completed
Last Updated

March 19, 2008

Status Verified

March 1, 2008

First QC Date

August 29, 2007

Last Update Submit

March 17, 2008

Conditions

Dilated Cardiomyopathy (DCM)

Interventions

blood testOTHER

looking at DNA

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with Dilated cardiomyopathy followed at the Heart Function Clinic and their families

You may qualify if:

  • Followed at MUHC Heart Function Centre
  • Documented EF of less than or equal to 35% and an enlarged heart with a left ventricular end-diastolic size of greater than 6 cm.
  • Patient's written consent

You may not qualify if:

  • Patients with a known underlying condition that results in a weakened and enlarged heart
  • Patients unable to read and understand the consent form
  • Patients who do not wish to participate

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Royal Victoria Hospital

Montreal, Quebec, H3A 1A1, Canada

RECRUITING

MeSH Terms

Conditions

Cardiomyopathy, Dilated

Interventions

Hematologic Tests

Condition Hierarchy (Ancestors)

CardiomegalyHeart DiseasesCardiovascular DiseasesCardiomyopathiesLaminopathiesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Intervention Hierarchy (Ancestors)

Clinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisInvestigative Techniques

Study Officials

  • Nadia S Giannetti, MD

    McGill University Hospital Centre

    PRINCIPAL INVESTIGATOR

  • Jamie Engert, PhD

    McGill University Health Centre/Research Institute of the McGill University Health Centre

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Nadia S Giannetti, MD

CONTACT

(514)934 1934nadia.giannetti@much.mcgill.ca

Study Design

Study Type
observational
Observational Model
FAMILY BASED
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

August 29, 2007

First Posted

August 31, 2007

Study Start

January 1, 2008

Study Completion

December 1, 2008

Last Updated

March 19, 2008

Record last verified: 2008-03

Locations

CA(1)